It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The incidence of neuroendocrine tumors (NETs) has been increasing in recent decades. Previously, we reported the incidence and survival of NETs in Taiwan by analyzing the 1996–2008 data from the Taiwan Cancer Registry. Here we performed an updated analysis on the incidence and survival of NETs in Taiwan from 1996 to 2015. The incidence of NETs was 0.244 per 100,000 in 1996 and increased to 3.162 per 100,000 in 2015. The most common site of NETs was rectum (29.65%), followed by lung/bronchus (17.22%), and pancreas (10.71%). The 5- and 10-year overall survival rates of all NETs were 54.6% and 45.3%, respectively. Female and younger NETs patients had a better survival. The survival of all NETs diagnosed between 2010 and 2015 was better than those diagnosed between 2004 and 2009. Among the common sites of NETs, an improved survival of pancreatic NETs diagnosed between 2010 and 2015 compared to those diagnosed between 2004 and 2009 was observed. Overall, the incidence of NETs in Taiwan has continued to increase. The survival of pancreatic NET has shown a recent improvement. The development of novel therapeutic agents has the potential to improve the prognosis of NETs of other sites in the near future.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan (GRID:grid.59784.37) (ISNI:0000000406229172)
2 National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan (GRID:grid.59784.37) (ISNI:0000000406229172); National Cheng Kung University, Department of Oncology, National Cheng Kung University Hospital, College of Medicine, Tainan, Taiwan (GRID:grid.64523.36) (ISNI:0000 0004 0532 3255); Kaohsiung Medical University Hospital, Department of Internal Medicine, Kaohsiung, Taiwan (GRID:grid.412027.2) (ISNI:0000 0004 0620 9374)
3 National Cheng Kung University, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, Tainan, Taiwan (GRID:grid.64523.36) (ISNI:0000 0004 0532 3255); National Cheng Kung University, Institute of Clinical Medicine, Tainan, Taiwan (GRID:grid.64523.36) (ISNI:0000 0004 0532 3255)
4 National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan (GRID:grid.59784.37) (ISNI:0000000406229172); Show Chwan Memorial Hospital, Department of Pathology, Changhua, Taiwan (GRID:grid.452796.b) (ISNI:0000 0004 0634 3637); Fu Jen Catholic University, School of Medicine, College of Medicine, New Taipei City, Taiwan (GRID:grid.256105.5) (ISNI:0000 0004 1937 1063)